Floatz logo

Dactinomycin

Spindle Cell Rhabdomyosarcoma

Explore 4 assets in Spindle Cell Rhabdomyosarcoma →
Floatz Rating
B60/100
Confidence
Indicative
v0.2
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.

No trial-level evidence is linked to this axis yet.

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Spindle Cell Rhabdomyosarcoma

AssetSponsorPhaseRating
Dactinomycin (this asset)Children's Oncology GroupP3B · 60
Vinorelbine DitartrateChildren's Oncology GroupP3B
Vincristine SulfateChildren's Oncology GroupP3B
CyclophosphamideChildren's Oncology GroupP3B

Other indications for Dactinomycin

IndicationSponsorPhaseRating
Kidney Cancer—P3BB · 65
Botryoid Rhabdomyosarcoma—P3B · 60
Alveolar Rhabdomyosarcoma—P3B · 60

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Dactinomycin in Spindle Cell Rhabdomyosarcoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/dactinomycin-spindle-cell-rhabdomyosarcoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →